BioAlliance Pharma announces preliminary results
Paris, 22 April 2008 - BioAlliance Pharma SA (Euronext Paris - BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections, in cancer and HIV, today announced the preliminary positive results for its US pivotal Phase III clinical trial with LoramycTM (miconazole Lauriad®), Mucoadhesive Buccal Tablets (MBT) developed for the treatment of OroPharyngeal Candidiasis in immunocompromised population.
More info on BioAlliance's website or on the press release.
Next > Capricorn Venture Partners closes its Cleantech Fund at € 100 million Previous > TiGenix gives business update |
